AstraZeneca Pharma India Q1 net profit declines 13 pc at Rs 18.63 cr

Drug firm AstraZeneca Pharma India on Monday reported a 13.38 per centdecline in its net profit to Rs 18.63 crore for the quarter ended June.

AstraZeneca Pharma India Q1 net profit declines 13 pc at Rs 18.63 cr
Press Trust of India New Delhi
1 min read Last Updated : Aug 10 2020 | 6:07 PM IST

Drug firm AstraZeneca Pharma India on Monday reported a 13.38 per centdecline in its net profit to Rs 18.63 crore for the quarter ended June.

The company had posted a net profit of Rs 21.51 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a BSE filing.

Revenue from operations stood at Rs 193.57 crore for the quarter under consideration. It was Rs 204.56 crore for the same periodyear ago, it added.

The board of directors has declared an interim dividend of Rs 2 per equity share for the financial year 2020-21, the filing said.

Shares ofAstraZeneca Pharma India were trading at Rs3,381.65per scrip on BSE, up 1.50 per cent over previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusAstraZenecaPharma

First Published: Aug 10 2020 | 5:50 PM IST

Next Story